Upgrade to SI Premium - Free Trial

Pfizer (PFE) Reports Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results at ESC Congress 2018

August 27, 2018 5:40 AM
Pfizer Inc. (NYSE: PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles